Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
- Asahi Kasei Pharma’s Apr-Sep Sales Up 6% Due to Doubled Recomodulin Sales
November 4, 2011
- Once-Yearly Dosing Osteoporosis Agent Starts PIII Study: Asahi Kasei Pharma
November 4, 2011
- FDA Assigns Action Date of Jan 25, 2012 for Takeda’s Alogliptin
November 4, 2011
- Sales of Medical & Pharmaceutical Business Increased 2.4% Driven by New Drugs: Teijin
November 4, 2011
- Astellas: Sales, Profits Up in First Half Driven by Vesicare
November 4, 2011
- Eisai Announces Double-digit Declines in 1st-Half Sales, Profits
November 4, 2011
- Anti-androgen Drug MDV3100 Significantly Improves OS in PIII AFFIRM Trial: Astellas
November 4, 2011
- Complaints of Side Effects from Lyrica Up Sharply: Nextit Research
November 4, 2011
- Miraca HD: Sales, Profits Up due to Addition of Innogenetics NV
November 4, 2011
- Kaken: Mainstay Products, Generics Pull Business
November 4, 2011
- Santen Sends Expert Researchers to US, Europe to Assess Candidate Compounds for In-licensing
November 4, 2011
- Santen Reports Steady 5.3% Increase in Sales in Domestic, Overseas Markets in Apr-Sep
November 2, 2011
- Eisai President Says Japan, China to Become Key Battlefields for Aricept
November 2, 2011
- Bayer Yakuhin to Reorganize Structure, Offer Early Retirement Program to 150
November 2, 2011
- AstraZeneca’s 9-Month Global Sales Fell Due to Competition with Generics
November 2, 2011
- Profits Show Double-Digit Drop Due to Increased R&D Costs: Torii
November 2, 2011
- Daiichi Sankyo Suspends PII Trials in US, Europe for Post-Surgery VTE Prevention
November 2, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…